Table 3 Univariate log-rank analyses for prognostic factors in 86 patients with follow-up
Parameters | Category | No. of patients with follow-up | OS | MeFS | ||
|---|---|---|---|---|---|---|
No. of event | P-value | No. of event | P-value | |||
Sex | Male | 47 | 12 | 0.7680 | 15 | 0.3483 |
Female | 39 | 10 | 15 | |||
Age | <60 years | 32 | 7 | 0.1517 | 8 | 0.0333* |
≥60 years | 54 | 15 | 22 | |||
Location | Extremity | 66 | 17 | 0.6290 | 23 | 0.5839 |
Axial | 20 | 5 | 7 | |||
Tumor size | <6 cm | 42 | 9 | 0.1762 | 10 | 0.0124* |
≥6 cm | 41 | 12 | 19 | |||
Tumor depth | Superficial | 33 | 5 | 0.0321* | 7 | 0.0162* |
Deep | 53 | 17 | 23 | |||
Myxoid area | ≥75% | 25 | 3 | 0.1381 | 4 | 0.0576 |
<75% | 61 | 19 | 26 | |||
Necrotic area | <10% | 59 | 13 | 0.1378 | 15 | 0.0010* |
≥10% | 27 | 9 | 15 | |||
Mitotic count | <20/10 HPFs | 70 | 13 | <0.0001* | 18 | <0.0001* |
≥20/10 HPFs | 16 | 9 | 12 | |||
FNCLCC grade | Grade 1 | 39 | 5 | 0.0437* | 6 | 0.0030* |
Grades 2 and 3 | 47 | 17 | 24 | |||
AJCC stage | Stages I and II | 49 | 9 | 0.0354* | 12 | 0.0056* |
Stage III | 34 | 12 | 17 | |||
MET expression | Low expression (<30%) | 28 | 1 | 0.0032* | 2 | 0.0007* |
Overexpression (≥30%) | 58 | 21 | 28 | |||
